Core Viewpoint - The company, Canar Medical Technology Co., Ltd., a wholly-owned subsidiary of Canar Co., has recently received three utility model patent certificates from the National Intellectual Property Administration of China, indicating a significant advancement in its product offerings [1] Group 1 - The patents awarded include "A Pressure-Resistant Anti-Backflow Infusion Pipeline," "Pressure Display Syringe," and "Fixed Measurement Syringe," showcasing the company's innovation in medical technology [1]

Group 1 - The core point of the article is that Canar Medical Technology Co., Ltd., a wholly-owned subsidiary of Canar Co., has recently received patent certificates from the National Intellectual Property Administration for three medical products [2] - The patents granted include "a pressure-resistant anti-backflow infusion pipeline," "a pressure display syringe," and "a fixed measurement syringe" [2] - For the fiscal year 2024, Canar's revenue composition is as follows: medical products account for 51.23%, veterinary products for 39.03%, laboratory consumables for 7.61%, and others for 2.13% [2]

证券代码：301122 证券简称：采纳股份 公告编号：2025-076 采纳科技股份有限公司 关于全资子公司取得专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 采纳科技股份有限公司（以下简称"公司"）全资子公司江苏采纳医疗科技 有限公司（以下简称"采纳医疗"），于近日收到国家知识产权局颁发的专利证 书，具体情况如下： | 序号 | 专利名称 | 专利类型 | 专利号 | 专利权人 | 授权公告日 | | --- | --- | --- | --- | --- | --- | | 1 | 一种耐压防逆流输 | 实用新型 | ZL | 采纳医疗 | 2025年08月 | | | 液管路 | | 202421897663.3 | | 19 日 | | 2 | 压力显示注射器 | 实用新型 | ZL | 采纳医疗 | 2025年08月 | | | | | 202421897901.0 | | 19 日 | | 3 | 固定计量注射器 | 实用新型 | ZL | 采纳医疗 | 2025年08月 | | | | | 202421898995.3 | | 1 ...

证券代码：301122 证券简称：采纳股份 公告编号：2025-075 采纳科技股份有限公司 关于使用部分闲置募集资金和自有资金 进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 采纳科技股份有限公司（以下简称"公司"）召开的第三届董事会第十二次 会议、第三届监事会第十一次会议、2025 年第一次临时股东大会，分别审议通 过了《关于使用部分闲置募集资金和自有资金进行现金管理的议案》，同意公司 及全资子公司在确保不影响募集资金投资项目和公司正常经营，并有效控制风险 的前提下，使用额度不超过人民币 20,000 万元（含本数）的闲置募集资金（含 超募资金）和额度不超过人民币 80,000 万元（含本数）的自有资金进行现金管 理。使用期限自股东大会审议通过之日起 12 个月内有效。在上述额度和期限内， 资金可循环滚动使用。 同时，在额度范围内授权公司管理层行使相关投资决策权并签署相关文件， 具 体 由 公 司 财 务 部 负 责 组 织 实 施 。 具 体 内 容 详 见 公 司 在 巨 潮 资 讯 网 （www.cninfo.com.cn）披 ...

归创通桥(02190)发布公告，于2025年8月19日，董事会审议及批准有关建议采纳股份（301122）激励计 划的决议案。股份激励计划将以发行新H股(包括转让库存股)拨资，因而构成《上市规则》第十七章所 界定涉及公司发行新股份的股份计划。采纳股份激励计划须待股东批准后，方可作实。 ...

Core Viewpoint - The company, Zhichuang Tongqiao (02190), announced the approval of a proposed share incentive plan by its board of directors, which is set to be reviewed on August 19, 2025, and requires shareholder approval to be implemented [1] Group 1 - The share incentive plan will involve the issuance of new H-shares, including the transfer of treasury shares, thus constituting a share plan as defined under Chapter 17 of the Listing Rules [1] - The implementation of the share incentive plan is contingent upon receiving approval from the shareholders [1]

Group 1 - The stock price of CaiNa Co., Ltd. was 23.57 yuan as of August 14, 2025, down 0.97 yuan or 3.95% from the previous trading day's closing price [1] - The company operates in the medical device sector, focusing on the research, production, and sales of medical devices [1] - On August 14, 2025, a block trade occurred involving 1.6575 million shares at a transaction value of 33.9953 million yuan, with a transaction price of 20.51 yuan, representing a 12.98% discount to the closing price [1] Group 2 - The block trade accounted for 52.90% of the total transaction value on that day [1] - On August 14, 2025, the net outflow of main funds for CaiNa Co., Ltd. was 703,900 yuan, which is 0.04% of the circulating market value [1] - Over the past five days, the net outflow of main funds totaled 21.9651 million yuan, representing 1.38% of the circulating market value [1]

| 交易日期 | 证券代码 | 证券简称 | 成交价格 (元) | 成交量 (万股/万份) | 成交全额 买方营业部 (万元) | | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-08-14 | 301122 | 采纳股份 | 20.51 | 165.75 | 3,399.53 万宏源证券有限 | | 机构专用 | | | | | | | | 公司上海金山区蒙 | | | | | | | | | 山路证券营业部 | | 8月14日，采纳股份大宗交易成交165.75万股，成交额3399.53万元，占当日总成交额的34.6%，成交价20.51元，较市场收盘 价23.57元折价12.98%。 ...

证券日报网讯采纳股份（301122）8月12日在互动平台回答投资者提问时表示，截至2025年8月8日，在 中国证券登记结算有限责任公司深圳分公司登记在册的公司股东数为8411户。 ...

序号股票简称PE(TTM)PE(静)市净率总市值(元)13采纳股份85.1357.281.6730.41亿行业平均 56.5652.664.92118.97亿行业中值39.7639.192.9457.67亿1九安医疗11.2811.400.89190.28亿2英科医疗 15.1416.331.35239.25亿3山东药玻16.1616.211.86152.83亿4振德医疗16.7615.801.0760.86亿5新华医疗 17.1715.911.40110.05亿6奥美医疗17.1816.831.7762.06亿7九强生物17.8916.632.1988.59亿8康德莱 18.3218.341.5239.49亿9维力医疗18.6219.892.3443.64亿10奥泰生物18.7119.731.5159.67亿11鱼跃医疗 20.1519.762.72356.78亿12三鑫医疗20.8121.623.6549.16亿 来源：金融界 采纳科技股份有限公司的主营业务是注射穿刺器械及实验室耗材的研发、生产和销售。公司的主要产品 是医疗器械、动物器械、实验室耗材等。公司被认定为江苏省专精特新中小企业、农业产业化省级龙 ...